Literature DB >> 35785381

The efficacy of posterior wall isolation in atrial fibrillation ablation: A systematic review and meta-analysis of randomized controlled trials.

Chanavuth Kanitsoraphan1, Pattara Rattanawong2, Chol Techorueangwiwat1, Jakrin Kewcharoen3, Raktham Mekritthikrai4, Narut Prasitlumkum5, Parthav Shah1, Hicham El Masry2.   

Abstract

Background: Posterior wall isolation (PWI) is an emerging approach in atrial fibrillation (AF) ablation, yet its efficacy remains controversial. This is the first meta-analysis of randomized controlled trials (RCT) to evaluate the efficacy of PWI in AF ablation. Objective: To assess the efficacy of PWI in reducing atrial arrhythmia recurrence following initial AF ablation at long-term follow-ups when compared to conventional methods.
Methods: We conducted a literature search from inception through September 2021 in EMBASE and MEDLINE databases. We included RCTs that compared outcomes in PWI and conventional approaches of AF ablation. Data from each study were combined using the random-effects, generic inverse variance method of DerSimonian and Laird to calculate odds ratio (OR), and 95% confidence interval (CI).
Results: Eight RCT from 2009 to 2020, including 1024 AF patients, were included. PWI did not decrease overall atrial arrhythmias recurrence (RR 0.96, 95% CI:0.88-1.05, I 2 = 31.6%, p-value 0.393). However, the pooled analysis showed a significant decrease in AF recurrence in PWI compared to controlled approaches (RR 0.88, 95% CI:0.81-0.96, I 2 = 48.2%, p-value .004). In the subgroup analysis, PWI significantly decreased AF recurrence in the studies that included only persistent AF (RR = 0.89, 95% CI:0.80-0.98, I 2 = 65.2%, p-value .014). PWI significantly decreased AF recurrence when compared to PVI with roof line (RR 0.84, 95% CI 0.74-0.95, I 2 0.00%, p-value .008).
Conclusion: Our study suggests that adding PWI significantly decreased AF recurrence in patients with persistent AF compared to controlled approaches. It highlights the importance of considering PWI during the initial procedure in this patient population.
© 2022 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.

Entities:  

Year:  2022        PMID: 35785381      PMCID: PMC9237313          DOI: 10.1002/joa3.12698

Source DB:  PubMed          Journal:  J Arrhythm        ISSN: 1880-4276


INTRODUCTION

AF ablation is an established treatment in patients with symptomatic atrial fibrillation (AF). Atrial fibrillation ablation, when compared to medication therapy, has been shown effective in reducing AF recurrence, symptomatic AF, and AF burden. , , , The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement recommends catheter ablation for patients with symptomatic AF that is refractory or intolerant to at least one class I or III antiarrhythmic medication (Class I recommendation for paroxysmal AF [PAF], class IIa for persistent AF [PeAF], and class IIb for long‐standing PeAF). Pulmonary vein isolation (PVI) has been a standard approach for AF ablation. Additional ablation targets have been proposed to improve outcomes; however, there has been no class I recommendations for routine additional ablation in conjunction with PVI. Posterior wall isolation (PWI) is a promising emerging technique to improve AF ablation efficacy, particularly in patients who tend to have higher recurrence rates. However, the technique has faced challenges regarding its efficacy and safety since previous studies showed inconsistent data. The current guideline suggested PWI might be considered in initial or repeat ablation in PeAF or long‐standing PeAF (Class IIb). The STAR AF II trial suggested no benefits of additional lines performed beyond PVI in patients with PeAF. As more evidence on the efficacy of PWI emerges, this is the first meta‐analysis of RCT to evaluate the efficacy of PWI in AF ablation.

METHODS

Search strategy

The professional librarian performed the literature search from the EMBASE, PubMed, Scopus, Web of Science, and Cochrane databases from inception to September 2021 using a search strategy that includes the term “atrial fibrillation,” “pulmonary vein isolation,” “posterior wall isolation,” and “box isolation”. We manually reviewed references from review articles and systematic reviews for additional studies. Only full articles in English and studies conducted in RCTs were included. The quality assessment and bias risk assessment of the selected studies were conducted.

Inclusion and exclusion criteria

The eligibility criteria included the following. (1) Randomized control trial studies reporting endpoints of atrial fibrillation or atrial arrhythmia recurrence after AF ablation with or without PWI. (2) Adjusted or unadjusted RR with 95% confidence interval, or adequate raw data for calculation were provided. Study eligibility was independently determined by two investigators (CK and PR), and differences were resolved by mutual consensus. Studies with overlap or duplicated populations were excluded.

Data extraction

The included studies were reviewed for the type of study, country of origin, type of AF, total population, mean age, PWI techniques and techniques in control arms, mean follow‐up, the definition of recurrence, and conclusion. Extracted data were collected using standardized forms. Overall atrial arrhythmia was defined as the combination of AF, atrial flutter, or atrial tachycardia.

Statistical analysis

We performed a meta‐analysis of the included studies using a fixed‐effect model. We pooled the point estimates of RR from each study using the generic inverse‐variance method of Der Simonian and Laird. Heterogeneity was quantified using the I 2 statistics, which range from 0 to 100% and I 2 > 50% indicates substantial heterogeneity. Publication bias was assessed using a funnel plot, and Egger's regression test with a p‐value of <.05 was considered significant. All statistical analyses were performed using Stata version 14.2 TX: StataCorp; 2015.

RESULTS

Search results

Our search strategy yielded 763 potentially relevant articles (331 articles from EMBASE, 276 articles from PubMed, 78 from Scopus, 74 from Web of Science, and 4 from the Cochrane database). After the exclusion of duplicated articles, 600 articles underwent title and abstract review. At this stage, 567 articles were excluded as they were not randomized controlled trials, were not conducted in AF patients, or the titles and abstracts were not relevant. This left 33 articles for full‐length review. A further 25 studies were excluded as they were overlap or duplicated patients' populations or did not report outcomes and did not provide sufficient data to calculate RR. Therefore, a total of 8 studies were included in this meta‐analysis. Figure 1 outlines the search and literature review process.
FIGURE 1

Search methodology and selection process

Search methodology and selection process

Descriptions of included studies

Eight studies with a total of 1024 AF patients undergoing initial AF ablation were analyzed and included in this meta‐analysis. , , , , , , , , Of these patients, 512 (50.0%) underwent PWI and 512 (50.0%) underwent controlled approaches. One hundred and seventy‐eight (34.8%) undergoing PWI and 189 patients (36.9%) undergoing controlled approaches had atrial arrhythmia recurrence at follow‐up. The characteristics of included studies are outlined in Table 1.
TABLE 1

Summarized characteristics of individual included studies

First author, yearCountryInstitutionsType of AFNPosterior Wall isolation ablation techniqueControlMean follow up (months)Recurrence definitionComplicationsConclusion
Aryana, 2020

USA

Japan

Japan Red Cross Yokohama‐city Bay Hospital and Mercy General Hospital and Dignity Health Heart and Vascular Institute

PeAF/LSPe AF110

CPVI (cryoballoon) + PWI (cryoballoon ablation of bounded by LA roof, left pulmonary vein, right pulmonary vein, and posterior inferior border) + CTI

CPVI (cryoballoon) + CTI

12

AF,AT, atrial flutter >30 seconds

Method: ECG at each follow‐up visit, 7‐day to 14‐day mobile cardiac telemetry monitoring at 3, 6, and 12 months post‐ablation, unless a cardiac implantable electronic device existed.

PWI: 1 persistent phrenic nerve palsy, 1 bradycardia requiring pacemaker, 1 groin vascular complication

Control: 1 Heart failure exacerbation, 1 Pericarditis, 1 Pericardial effusion

PVI + PWI using cryoballoon is associated with a significant reduction in atrial fibrillation recurrence
Chilukuri, 2011USAThe John Hopkins HospitalPAF 79%, PeAF 21%30

Single ring (box) isolation: single continuous lesions at the anterior aspect of PV joined with a roof line superiorly and a floor line inferiorly

CPVI (without interpulmonary isthmus line)

10 ± 2

AF, AT, atrial flutter >30 seconds

Method: Daily 30‐second measurement of heart rhythm with the portable ECG monitoring device

PWI: 1 embolic stroke, 1 cardiac tamponade, 1 femoral arterial pseudoaneurysm, 1 abdominal wall hematoma

Control: None

The efficacy of box isolation is similar to circumferential PVI protocol for AF ablation.
JS Kim, 2014KoreaKorea University Guro HospitalPeAF

120

CPVI (without interpulmonary isthmus line) + POBI (linear ablation along the roof and posterior inferior wall) + anterior wall of LA + CTI

CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof + anterior wall of LA + CTI

12

AF or atrial flutter

Method: ECG at every visit, 48‐hour Holter monitoring at 1, 3, 6, and 12 months.

PWI: None

Control: None

Additional POBI after anterior wall linear lesions and PVI can reduce AF recurrence in PeAF
Lee, 2019Korea

Kyung Hee University Medical College, Korea University Cardiovascular

Center, Ewha Womans University, Yonsei University Health System, and Hanyang University

PeAF217

CPVI + POBI (linear ablation along the roof and posterior inferior wall) + CTI

CPVI + CTI

16.2 ± 8.8

AF or AT >30 seconds

Method: ECG at every visit and 24‐hour Holter at 3 and 6 months and then every 6 months thereafter

PWI: 4 cardiac tamponades, 2 sinus node dysfunction, 1 atrioesophageal fistula, 3 pericarditis, 2 pseudoaneurysm

Control: 4 cardiac tamponade, 1 SA node dysfunction, 1 atrioesophageal fistula, 1 pericarditis

In patients with PeAF, an empirical POBI did not improve the rhythm outcome of the catheter ablation
Lim, 2012Australia, SingaporeWestmead Hospital (Australia), National University Hospital (Singapore), Liverpool hospital and University of New South Wales (Australia)PAF, PeAF or long‐standing AF220

Single‐ring (box) isolation: single continuous lesions at the anterior aspect of PV joined with a roof line superiorly and a floor line inferiorly + CTI

Wide antral isolation: CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof + CTI

24

AF,AT, atrial flutter >30 seconds

Method: ECG or 7‐day Holter at 6 and 12 months.

PWI: 1 cardiac tamponade, 2 ischemic stroke

Control: 1 cardiac tamponade, 1 ischemic stroke

Single‐ring isolation resulted in fewer AF recurrences than wide antral isolation, although organized AT and overall atrial arrhythmia recurrences were similar.
Mun, 2012KoreaYonsei University Health SystemPAF156

CPVI + POBI (linear ablation along the roof and posterior inferior wall)

CPVI

15.6 ± 5.0

AF or AT >30 seconds

Method: ECG at every visit. 24‐hour/ 48‐hour and/or event recorder at 3, 6, and 12 months.

PWI: 3 pericarditis

Control: 1 pericardial effusion, 1 percarditis

Additional linear POBI ablations to CVPI did not improve clinical outcome.

Pak, 2020

(PEACEFUL)

Korea

Yonsei University Health System,

Korea University Cardiovascular Center, and Ewha Womans

University

PeAF who converted to PAF by AAD114

CPVI + POBI (linear ablation along the roof and posterior inferior wall) + CTI (posterior inferior linear ablation)

CPVI + CTI

23.8 ± 10.2

AF or AT >30 seconds

Method: ECG at every visit, 24‐hour Holder at 3 and 6 months and then every 6 months

PWI: 1 phrenic nerve palsy

Control: 1 femoral AV fistula, 1 hemopericardium, 1 left inferior pulmonar vein stenosis

The addition of POBI to CVPI did not improve the outcome in patients with PeAF who previously converted to PAF by AAD.
Tamborero, 2009SpainUniversity of Barcelona Hospital Clinic and Universitari de Barcelona Hospital ClinicPAF, PeAF or long‐standing AF120

CPVI + POBI (linear ablation along the roof and posterior inferior wall)

CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof

9.8 ± 4.3

AF or atrial flutter

Method: 48‐hour Holter monitoring before visits at 1, 4 and 7 months, then every 6 months.

PWI: 1 transient cerebrovascular ischemia, 1 transient inferior myocardial ischemia

Control: 2 transient cerebrovascular ischemia, 1 transient inferior myocardial ischemia

Isolation of the left atrial posterior wall did not offer additional benefit over a single roof line lesion after CPVI.

Abbreviations: AAD, antiarrhythmic drugs; AF, atrial fibrillation; AT, atrial tachycardia; CS, coronary sinus; CVPI, circumferential pulmonary vein isolation; IVC, inferior vena cava; POBI, posterior box isolation; CTI, cavotricuspid isthmus; LA, left atrium; LIPV, left inferior pulmonary vein; LSPe AF, Long‐standing persistent AF; LSPV, left superior pulmonary vein; PeAF, Persistent AF; PAF, Paroxysmal AF; PWI, posterior wall isolation; RIPV, right inferior pulmonary vein; RSPV; right superior pulmonary vein; SVC, superior vena cava.

Summarized characteristics of individual included studies USA Japan Japan Red Cross Yokohama‐city Bay Hospital and Mercy General Hospital and Dignity Health Heart and Vascular Institute CPVI (cryoballoon) + PWI (cryoballoon ablation of bounded by LA roof, left pulmonary vein, right pulmonary vein, and posterior inferior border) + CTI CPVI (cryoballoon) + CTI AF,AT, atrial flutter >30 seconds Method: ECG at each follow‐up visit, 7‐day to 14‐day mobile cardiac telemetry monitoring at 3, 6, and 12 months post‐ablation, unless a cardiac implantable electronic device existed. PWI: 1 persistent phrenic nerve palsy, 1 bradycardia requiring pacemaker, 1 groin vascular complication Control: 1 Heart failure exacerbation, 1 Pericarditis, 1 Pericardial effusion Single ring (box) isolation: single continuous lesions at the anterior aspect of PV joined with a roof line superiorly and a floor line inferiorly CPVI (without interpulmonary isthmus line) AF, AT, atrial flutter >30 seconds Method: Daily 30‐second measurement of heart rhythm with the portable ECG monitoring device PWI: 1 embolic stroke, 1 cardiac tamponade, 1 femoral arterial pseudoaneurysm, 1 abdominal wall hematoma Control: None 120 CPVI (without interpulmonary isthmus line) + POBI (linear ablation along the roof and posterior inferior wall) + anterior wall of LA + CTI CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof + anterior wall of LA + CTI AF or atrial flutter Method: ECG at every visit, 48‐hour Holter monitoring at 1, 3, 6, and 12 months. PWI: None Control: None Kyung Hee University Medical College, Korea University Cardiovascular Center, Ewha Womans University, Yonsei University Health System, and Hanyang University CPVI + POBI (linear ablation along the roof and posterior inferior wall) + CTI CPVI + CTI AF or AT >30 seconds Method: ECG at every visit and 24‐hour Holter at 3 and 6 months and then every 6 months thereafter PWI: 4 cardiac tamponades, 2 sinus node dysfunction, 1 atrioesophageal fistula, 3 pericarditis, 2 pseudoaneurysm Control: 4 cardiac tamponade, 1 SA node dysfunction, 1 atrioesophageal fistula, 1 pericarditis Single‐ring (box) isolation: single continuous lesions at the anterior aspect of PV joined with a roof line superiorly and a floor line inferiorly + CTI Wide antral isolation: CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof + CTI AF,AT, atrial flutter >30 seconds Method: ECG or 7‐day Holter at 6 and 12 months. PWI: 1 cardiac tamponade, 2 ischemic stroke Control: 1 cardiac tamponade, 1 ischemic stroke CPVI + POBI (linear ablation along the roof and posterior inferior wall) CPVI AF or AT >30 seconds Method: ECG at every visit. 24‐hour/ 48‐hour and/or event recorder at 3, 6, and 12 months. PWI: 3 pericarditis Control: 1 pericardial effusion, 1 percarditis Pak, 2020 (PEACEFUL) Yonsei University Health System, Korea University Cardiovascular Center, and Ewha Womans University CPVI + POBI (linear ablation along the roof and posterior inferior wall) + CTI (posterior inferior linear ablation) CPVI + CTI AF or AT >30 seconds Method: ECG at every visit, 24‐hour Holder at 3 and 6 months and then every 6 months PWI: 1 phrenic nerve palsy Control: 1 femoral AV fistula, 1 hemopericardium, 1 left inferior pulmonar vein stenosis CPVI + POBI (linear ablation along the roof and posterior inferior wall) CPVI (without interpulmonary isthmus line) + LA linear ablation on the roof AF or atrial flutter Method: 48‐hour Holter monitoring before visits at 1, 4 and 7 months, then every 6 months. PWI: 1 transient cerebrovascular ischemia, 1 transient inferior myocardial ischemia Control: 2 transient cerebrovascular ischemia, 1 transient inferior myocardial ischemia Abbreviations: AAD, antiarrhythmic drugs; AF, atrial fibrillation; AT, atrial tachycardia; CS, coronary sinus; CVPI, circumferential pulmonary vein isolation; IVC, inferior vena cava; POBI, posterior box isolation; CTI, cavotricuspid isthmus; LA, left atrium; LIPV, left inferior pulmonary vein; LSPe AF, Long‐standing persistent AF; LSPV, left superior pulmonary vein; PeAF, Persistent AF; PAF, Paroxysmal AF; PWI, posterior wall isolation; RIPV, right inferior pulmonary vein; RSPV; right superior pulmonary vein; SVC, superior vena cava.

Overall meta‐analysis results

In the overall pooled analysis of 8 studies, PWI was not significantly associated with a decrease in overall atrial arrhythmia recurrences (RR 0.96, 95% CI 0.88–1.05, I 2 = 31.6%, p‐value .393) (Figure 2). However, 6 of 8 studies , , , , , reported AF recurrence as an outcome, in which pooled analysis showed that PWI significantly decreased the risk of AF recurrence (RR 0.88, 95% CI 0.81–0.96, I2 48.4%, p‐value .003) (Figure 3).
FIGURE 2

(A) Forest plot of PWI and overall atrial arrhythmia recurrences stratified by a subgroup of PWI versus PVI without roof line and PWI versus PVI with roof line. (B) Forest plot of PWI and overall atrial arrhythmia recurrences stratified by subgroup of PeAF and PeAF with PAF

FIGURE 3

(A) Forest plot of PWI and AF recurrences stratified by the subgroup of PWI versus PVI without roof line and PWI versus PVI with roof line; (B) Forest plot of PWI and AF recurrences stratified by a subgroup of PeAF and PeAF with PAF

(A) Forest plot of PWI and overall atrial arrhythmia recurrences stratified by a subgroup of PWI versus PVI without roof line and PWI versus PVI with roof line. (B) Forest plot of PWI and overall atrial arrhythmia recurrences stratified by subgroup of PeAF and PeAF with PAF (A) Forest plot of PWI and AF recurrences stratified by the subgroup of PWI versus PVI without roof line and PWI versus PVI with roof line; (B) Forest plot of PWI and AF recurrences stratified by a subgroup of PeAF and PeAF with PAF

Outcomes by type of AF

Persistent AF

Four studies included a total of 547 PeAF patients undergoing initial AF ablation (273 PWI and 274 controlled approaches). , , , AF recurred in 59 patients (21.5%) undergoing PWI and 84 patients (30.3%) undergoing controlled approaches. Atrial arrhythmias recurred in 72 patients (26.3%) undergoing PWI and 92 patients (33.2%) undergoing a controlled approach. Pooled analysis demonstrated that PWI significantly decrease AF recurrences (RR 0.88, 95% CI 0.80–0.97, I 2 65.5%, p‐value .019) (Figure 3B) but did not decrease overall atrial arrhythmia recurrences (RR 0.91, 95% CI 0.81–1.01, I 2 51.4%, p‐value .073) in PeAF population (Figure 2B).

Paroxysmal and persistent AF

Four studies involved 473 non‐specific AF patients (included both PeAF and PAF) undergoing initial AF ablation (238 PWI and 235 controlled approaches). , , , Atrial arrhythmias recurred in 106 patients (39.6%) undergoing PWI and 97 patients (36.1%) undergoing the conventional approach. Pooled analysis demonstrated that PWI did not decrease AF recurrences (RR 0.87, 95% CI 0.75–1.02, I 2 0.00%, p‐value .090) (Figure 3B) as well as overall atrial arrhythmia recurrences (RR 1.05, 95% CI 0.91–1.22, I 2 0.0%, p‐value .515) (Figure 2B) in the non‐specific population of AF.

Outcomes by ablation approaches

PWI versus PVI without roof line

Five studies including a total of 564 patients undergoing initial AF ablation (282 PWI and 282 PVI without roof line) reported overall atrial arrhythmia recurrences. , , , , Three of which reported AF recurrences. , , Pooled analysis demonstrated that PWI did not decrease overall atrial arrhythmia recurrences (RR 0.98, 95% CI 0.88–1.08, I 2 14.8%, p‐value .657) (Figure 2A) or AF recurrences (RR 0.92, 95% CI 0.83–1.03, I 2 65.3%, p‐value .138) (Figure 2B).

PWI versus PVI with roof line

Three studies including a total of 460 patients undergoing initial AF ablation (230 PWI and 230 PVI with roof line) reported overall atrial arrhythmia and AF recurrences. , , Pooled analysis demonstrated that PWI significantly decreased AF recurrences (RR 0.84, 95% CI 0.74–0.95, I 2 0.0%, p‐value .008) (Figure 3A), but did not decrease overall atrial arrhythmia recurrences (RR 0.94, 95% CI 0.81–1.10, I 2 56.8%, p‐value .445) (Figure 2A) when compared to PVI with roof line.

Complications

There was no significant difference risk of vascular access (RR 1.02, 95% CI 0.99–1.04, I 2 0.0%, p‐value .222), pericardial effusion (RR 0.98, 95% CI 0.96–1.01, I 2 0.0%, p‐value .147), pericarditis (RR 1.02, 95% CI 0.99–1.04, I 2 1.8%, p‐value .240), and stroke or TIA (RR 1.00, 95% CI 0.97–1.03, I 2 0.0%, p‐value .950) between PWI and controlled approaches (Figure 4).
FIGURE 4

Forest plot of the risk of complications from PWI compared with controlled approaches

Forest plot of the risk of complications from PWI compared with controlled approaches

Sensitivity analysis

We conducted a sensitivity analysis by excluding one study at a time to assess the stability of the results of the meta‐analysis. None of the results were significantly altered in the overall analysis.

Publication and risk study bias

We examined the contour‐enhanced funnel plot of the included studies to investigate potential publication bias. No significant publication bias was observed on the funnel plot of overall atrial arrhythmias and AF; however, in the limitation of a small number of included study. (Figure 5A and Figure 5B, respectively). Meanwhile, there was no small study bias observed in the Egger's test on overall atrial arrhythmias and AF analysis (p = .192 and p = .174, respectively). The quality assessment and bias risk assessment of the selected studies are shown in Figure 6.
FIGURE 5

Funnel plot of (A) PWI and overall atrial arrhythmia recurrences; B) PWI and AF recurrences

FIGURE 6

The quality assessment and bias risk assessment of the selected studies; (A) risk of bias graph; (B) risk of bias summary

Funnel plot of (A) PWI and overall atrial arrhythmia recurrences; B) PWI and AF recurrences The quality assessment and bias risk assessment of the selected studies; (A) risk of bias graph; (B) risk of bias summary

DISCUSSION

We conducted a meta‐analysis of RCTs evaluating the addition of PWI to conventional ablation. The main finding from this meta‐analysis is that the addition of PWI did not significantly improve efficacy in reducing arrhythmia recurrence. In PAF, catheter ablation with radiofrequency or cryotherapy is known to be superior in maintaining sinus rhythm compared to antiarrhythmic therapy. , , , Nonetheless, therapy to maintain sinus rhythm in PeAF is less effective, and this reflects in weaker recommendations in the current guideline. The addition of left atrial roof line ablation was used by some investigators in an effort to improve clinical success, however increased risk of atrial flutter was noted on follow up (reference 14,18,19) An analysis of AF recurrence from the catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation (CABANA) trial suggested significantly reducing recurrence of any AF by 48% and symptomatic AF by 51%, when compared to drug therapy over 5 years of follow up. Although, the trial stipulates that all catheter ablation involved PVI, with additional ablation at the investigator's discretion. Whether additional PWI would benefit AF recurrence remains controversial. The posterior left atrial wall has a critical role in the initiation and maintenance of AF. Several anatomical and electrophysiologic properties increase the arrhythmogenicity of the posterior wall. Both the pulmonary veins and the posterior wall are embryologically derived from the same tissue (mediastinal myocardium). The posterior wall and PV also have shorter action potential durations and slower phase 0 upstroke velocity. The myocardial fibers’ orientation in the PV antra and posterior wall is distinct, allowing reentry from anisotropic conduction. Ganglionic plexi are most prevalent in the posterior wall of the left atrium. The posterior wall may be disproportionately affected by the pressure stress, and that has been correlated with low voltage and electrical scar. , , These areas of low voltage and electrical scar are predictive of poor outcomes after catheter ablation in persistent AF. The posterior wall has emerged as an additional target of ablation, especially in a patient undergoing ablation for persistent atrial fibrillation. Our study suggested that the addition of PWI significantly decreased AF recurrence in PeAF but failed to decrease overall atrial arrhythmia recurrence. A study by Lim et al. demonstrated that PWI increased the incidence of reentrant tachycardia, which is likely attributable to posterior wall reconnection or even persistent epicardial connection (possibly due to the inability to achieve transmural ablations). We suspect that the decrease in AF recurrence is offset by an increase in the risk of reentrant flutter. Larger randomized controlled trials are needed to elucidate the magnitude of this phenomenon. Importantly, our study showed that the addition of PWI was not associated with increased acute/short‐term complications. Whether increased thermal injury to the esophagus and risk of atrio‐esophageal fistula is associated with the addition PWI remains unclear: this is related to the rare occurrence of this complication but invites caution.

Different criteria/techniques for posterior wall isolation

There is slight heterogeneity in PWI techniques among studies included in this meta‐analysis, as outlined in Table 1. The key methods for PWI include a single ring , , and PVI plus box lesion set. , , There has also been emerging use of cryoablation with more recent generations, of which the efficacy compared to radiofrequency (RF) ablation remains controversial. , More data would be needed to elucidate the impact of cryoablation versus RF ablation on the finding from this meta‐analysis.

Comparison with other meta‐analyses

A recent meta‐analysis by Thiyagaragjah et al., which includes 17 studies, evaluated the efficacy and safety of PWI during AF ablation. The study concluded that PWI could be achieved in a large portion of cases with satisfactory 12‐month freedom of atrial arrhythmia. Of note, there were only three RCT comparing PWI with PVI directly, and the interpretation of combined conflicting data would be limited. Studies with cryoablation were excluded from the analysis.

Limitations

Our study has a few limitations. There was substantial heterogeneity among studies. Sensitivity analysis was undertaken. There is slight variation in techniques performed, patient population, and definitions of outcomes as outlined in Table 1. The number of participants included in the trial is relatively small and may lead to underpower in subgroup analyses. Moreover, there was a limitation of funnel plot interpretation from a small number of included studies.

CONCLUSIONS

Our study showed that the addition of PWI to routine PVI in AF ablation significantly decreased AF recurrences after AF ablation, particularly in patients with PeAF. There were no significant differences in overall atrial arrhythmia recurrences with the addition of PWI to routine PVI, highlighting the increased risk of reentrant arrhythmias after this intervention.
  33 in total

1.  Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study.

Authors:  Mélèze Hocini; Pierre Jaïs; Prashanthan Sanders; Yoshihide Takahashi; Martin Rotter; Thomas Rostock; Li-Fern Hsu; Frédéric Sacher; Sylvain Reuter; Jacques Clémenty; Michel Haïssaguerre
Journal:  Circulation       Date:  2005-12-13       Impact factor: 29.690

2.  Linear ablation in addition to circumferential pulmonary vein isolation (Dallas lesion set) does not improve clinical outcome in patients with paroxysmal atrial fibrillation: a prospective randomized study.

Authors:  Tae-Hoon Kim; Junbeom Park; Jin-Kyu Park; Jae-Sun Uhm; Boyoung Joung; Chun Hwang; Moon-Hyoung Lee; Hui-Nam Pak
Journal:  Europace       Date:  2014-10-21       Impact factor: 5.214

3.  Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation.

Authors:  Oussama M Wazni; Gopi Dandamudi; Nitesh Sood; Robert Hoyt; Jaret Tyler; Sarfraz Durrani; Mark Niebauer; Kevin Makati; Blair Halperin; Andre Gauri; Gustavo Morales; Mingyuan Shao; Jeffrey Cerkvenik; Rachelle E Kaplon; Steven E Nissen
Journal:  N Engl J Med       Date:  2020-11-16       Impact factor: 91.245

4.  Electrical Posterior Box Isolation in Persistent Atrial Fibrillation Changed to Paroxysmal Atrial Fibrillation: A Multicenter, Prospective, Randomized Study.

Authors:  Hui-Nam Pak; Junbeom Park; Je-Wook Park; Song-Yi Yang; Hee Tae Yu; Tae-Hoon Kim; Jae-Sun Uhm; Jong-Il Choi; Boyoung Joung; Moon-Hyoung Lee; Young-Hoon Kim; Jaemin Shim
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-07-28

5.  Treatment of atrial fibrillation by silencing electrical activity in the posterior inter-pulmonary-vein atrium.

Authors:  Jian Chen; Morten Kristian Off; Eivind Solheim; Peter Schuster; Per Ivar Hoff; Ole-Jørgen Ohm
Journal:  Europace       Date:  2008-03       Impact factor: 5.214

6.  The Electrical Isolation of the Left Atrial Posterior Wall in Catheter Ablation of Persistent Atrial Fibrillation.

Authors:  Jung Myung Lee; Jaemin Shim; Junbeom Park; Hee Tae Yu; Tae-Hoon Kim; Jin-Kyu Park; Jae-Sun Uhm; Jin-Bae Kim; Boyoung Joung; Moon-Hyoung Lee; Young-Hoon Kim; Hui-Nam Pak
Journal:  JACC Clin Electrophysiol       Date:  2019-10-30

7.  Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation.

Authors:  Robert S Oakes; Troy J Badger; Eugene G Kholmovski; Nazem Akoum; Nathan S Burgon; Eric N Fish; Joshua J E Blauer; Swati N Rao; Edward V R DiBella; Nathan M Segerson; Marcos Daccarett; Jessiciah Windfelder; Christopher J McGann; Dennis Parker; Rob S MacLeod; Nassir F Marrouche
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

8.  The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation.

Authors:  J L Cox; T E Canavan; R B Schuessler; M E Cain; B D Lindsay; C Stone; P K Smith; P B Corr; J P Boineau
Journal:  J Thorac Cardiovasc Surg       Date:  1991-03       Impact factor: 5.209

9.  Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Authors:  Douglas L Packer; Daniel B Mark; Richard A Robb; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Peter A Noseworthy; Yves D Rosenberg; Neal Jeffries; L Brent Mitchell; Greg C Flaker; Evgeny Pokushalov; Alexander Romanov; T Jared Bunch; Georg Noelker; Andrey Ardashev; Amiran Revishvili; David J Wilber; Riccardo Cappato; Karl-Heinz Kuck; Gerhard Hindricks; D Wyn Davies; Peter R Kowey; Gerald V Naccarelli; James A Reiffel; Jonathan P Piccini; Adam P Silverstein; Hussein R Al-Khalidi; Kerry L Lee
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

10.  Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study.

Authors:  Elena Arbelo; Esther Guiu; Pablo Ramos; Felipe Bisbal; Roger Borras; David Andreu; José María Tolosana; Antonio Berruezo; Josep Brugada; Lluís Mont
Journal:  J Am Heart Assoc       Date:  2014-09-05       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.